154825-97-5

Basic information

• Product Name: METHYL 2-(4-BROMOPHENYL)-2,2-DIMETHYLACETATE
• Synonyms: methyl 2-(4-bromophenyl)-2-methylpropanoate;α,α-diMethyl-(4-broMophenyl)acetic acid Methyl ester;Benzeneacetic acid,4-broMo-a,a-diMethyl-, Methyl ester;Benzeneacetic acid, 4-bromo-α,α-dimethyl-, methyl ester;2-(4-BROMOPHENYL)-2,2-DIMETHYLACETATE;p-Bromo-alpha,alpha-Dimethylphenylacetic acid methyl ester;2-methyl-2-(p-bromophenyl)propionic acid methyl ester;P-Bromo-a,a-DimethylPhenylaceticAcidMethylEster
• CAS NO: 154825-97-5
• Molecular Formula: C₁₁H₁₃BrO₂
• Molecular Weight: 257.12372
• EINECS: 1308068-626-2
• Product Categories: Intermediates;Miscellaneous Reagents;Aromatics Compounds;Aromatics
• Mol File: 154825-97-5.mol
• Article Data: 22

Chemical Properties

• Boiling Point: 290℃
• Flash Point: 129℃
• Appearance: Colourless oil
• Density: 1.337
• Vapor Pressure: 0.00209mmHg at 25°C
• Refractive Index: 1.522
• Storage Temp.: Refrigerator
• Water Solubility: 43mg/L at 20℃
• CAS DataBase Reference: METHYL 2-(4-BROMOPHENYL)-2,2-DIMETHYLACETATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 2-(4-BROMOPHENYL)-2,2-DIMETHYLACETATE(154825-97-5)
• EPA Substance Registry System: METHYL 2-(4-BROMOPHENYL)-2,2-DIMETHYLACETATE(154825-97-5)

Safety Data

• Hazardous Substances Data: 154825-97-5(Hazardous Substances Data)

Usage

Chemical Properties

Colourless Oil

Uses

Methyl 2-(4-Bromophenyl)-2,2-dimethylacetate (cas# 154825-97-5) is a compound useful in organic synthesis.

InChI:InChI=1/C11H13BrO2/c1-11(2,10(13)14-3)8-4-6-9(12)7-5-8/h4-7H,1-3H3

Upstream product

• 41841-16-1 (4-bromo-phenyl)-acetic acid methyl ester 
• 74-88-4 methyl iodide 
• 83636-46-8 methyl 2-(4-bromophenyl)propanoate 
• 1878-68-8 2-(4-bromophenyl)-acetic acid 
• 23426-63-3 2-bromo-2-methylpropionic acid methyl ester 
• 589-87-7 1,4-bromoiodobenzene 
• 71-43-2 benzene 
• 67-56-1 methanol 
• 32454-35-6 2-(4-bromophenyl)-2-methylpropionic acid 
• 1634-04-4 tert-butyl methyl ether 

Downstream Products

• 32454-35-6 2-(4-bromophenyl)-2-methylpropionic acid 
• 897935-07-8 5-[1-(4-bromophenyl)-1-methylethyl]-1H-1,2,4-triazol-3-amine 
• 32454-37-8 2,2-dimethyl-2-(4-bromophenyl)ethanol 
• 890839-10-8 methyl 2-methyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propanoate 
• 915084-42-3 2-(4-(benzyloxycarbonylamino)phenyl)-2-methylpropanoic acid methyl ester 
• 1021432-52-9 methyl 2-(4-cyclopropylphenyl)-2,2-dimethylacetate 
• 1075217-19-4 methyl 2-{4-[(7-amino-5-methyl[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)ethynyl]phenyl}-2-methylpropanoate 
• 1236409-22-5 2-(4-bromophenyl)-N-methoxy-N,2-dimethylpropionamide 
• 1236409-53-2 ethyl N-[4-(2-methoxy-1,1-dimethyl-2-oxoethyl)phenyl]-beta-alaninate 
• 1298022-54-4 methyl 2-methyl-2-(4-vinylphenyl)propanoate 
• 1000536-33-3 2-methyl-2-(4-(2-hydroxyethyl)phenyl)propionic acid methyl ester 
• 1181267-32-2 methyl 2-methyl-2-(4-(2-(methylsulfonyloxy)ethyl)phenyl)propanoate 
• 1181267-38-8 4-[2-[4-[1-(2-ethoxyethyl)-1H-benzimidazol-2-yl]-1-piperidine]ethyl]-α,α-dimethylphenylacetic acid methyl ester 
• 202189-78-4 Bilastine 

Relevant articles and documents

DIHYDROPYRIMIDINE COMPOUNDS AND USES THEREOF IN MEDICINE

Provided herein are a dihydropyrimidine compound and use as a medicament, especially application as a medicament used for treating and preventing hepatitis B. Specifically, provided herein is a compound having Formula (I) or (Ia), or a stereisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein the variables of the formulas are as defined in the specification. Also provided herein is use of the compound having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof as a medicament, especially use as a medicament for treating and preventing hepatitis B.

Dihydropyrimidine compound and uses of dihydropyrimidine compound in drugs

The present invention relates to a dihydropyrimidine compound and uses of the dihydropyrimidine compound as drugs, particularly as drugs for treatment and prevention of hepatitis B, particularly to acompound represented by a general formula (I) or (Ia) or an enantiomer, a diastereomer, a tautomer, a hydrate, a solvate or a pharmaceutically acceptable salt thereof, wherein each variable is definedin the specification. The invention further relates to uses of the compound represented by a general formula (I) or (Ia) or the enantiomer, the diastereomer, the tautomer, the hydrate, the solvate orthe pharmaceutically acceptable salt thereof as drugs, especially as drugs for treatment and prevention of hepatitis B. The formulas (I) and (Ia) are defined in the specification.

HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE

The present invention relates to compounds and methods which may be useful as inhibitors of HIF pathway activity for the treatment or prevention of cancer and other hypoxia-mediated diseases.